Study design and treatment
This trial was a three‐center, open‐label, single‐group, Phase 2 study. After confirming the baseline assessment, patients received a 30‐min infusion of nab‐paclitaxel (Abraxane®, Taiho Pharmaceutical Co., Ltd.) at a dose of 100 mg/m